Skip to main content
Clinical Trials/NCT04080271
NCT04080271
Completed
Not Applicable

Role of Positron Emission Tomography/Computed Tomography in Detecting Bone Metastases in Cancer Patients.

Assiut University1 site in 1 country66 target enrollmentNovember 1, 2019
ConditionsBone Metastases

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bone Metastases
Sponsor
Assiut University
Enrollment
66
Locations
1
Primary Endpoint
description of bone metastases detected by PET/CT in cancer patients.
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The aim of this study is to detect bone metastases by PET/CT examination in cancer patients.

Detailed Description

Bone is a fertile soil for dissemination of metastatic tumor cells which can cause either osteolytic ( destructive) or osteoblastic (sclerotic) or mixed lesions in advanced cancer. Bone metastases are most common throughout the axial skeleton, this leads to major complications referred to as skeletal-related events (SREs), the most frequently are the need for radiotherapy and pathological fractures, associated with increase life morbidity and decrease overall survival. Seeking accurate image modalities provides definite staging, determining the optimal strategy of treatment and precise evaluation to decrease the burden of complication. PET/CT is superior than 2-dimensional planar providing a better image quality and enables quantitation of tumor metabolism. Acquisition and fusion of PET with CT also allow for localization and morphologic evaluation of abnormalities, leading to increased specificity. The National Comprehensive Cancer Network (NCCN) guideline recommended PET/CT imaging in cancers with high risk skeletal metastases, PET has advantage than CT in diagnosing osteolytic lesions; but combining PET with CT, increase the detection of osteoblastic lesions. CT is recommended to evaluate structural integrity in revealing cortical integrity and the extent of structural destruction.

Registry
clinicaltrials.gov
Start Date
November 1, 2019
End Date
December 1, 2021
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Aalaa Wael Hussein

resident doctor

Assiut University

Eligibility Criteria

Inclusion Criteria

  • patients diagnosed with different types of malignant tumor, suspected or diagnosed to have bone metastases and will do PET/CT examination
  • patients diagnosed with different types of malignant tumor, with accidently discovered bone metastases during PET/CT examination.
  • patients conscious to provide informed consent.

Exclusion Criteria

  • pregnant women.
  • patients with blood sugar \> 200 mg/dL.
  • patients unable to sleep in a fixed position for 20 minutes.
  • severely ill patients who aren't capable of complying with study procedures or comatose patients.

Outcomes

Primary Outcomes

description of bone metastases detected by PET/CT in cancer patients.

Time Frame: one year

Analysis of number, type and SUVmax of metastatic bony lesions detected by PET/CT in cancer patients.

compare diagnostic performance of PET/CT, planar bone scintigraphy and SPECT/CT in detecting bone metastases

Time Frame: one year

compare sensitivity, specificity, PPV,NPV and accuracy

Secondary Outcomes

  • risk benefit of PET/CT examination in cancer patients(one year)

Study Sites (1)

Loading locations...

Similar Trials